Obtusilactone B from *Machilus thunbergii* targets barrier-to-autointegration factor to treat cancer

Wanil Kim, Ha-Na Lyu, Hyun-Sook Kwon, Ye Seul Kim, Kyung-Ha Lee, Do-Yeon Kim, Goutam Chakraborty, Kwan Yong Choi, Ho Sup Yoon, Kyong-Tai Kim

Department of Life Science, Division of Molecular and Life Science, Pohang University of Science and Technology, Pohang 790-784, Republic of Korea (W.K., H.-N.L., H.-S.K., Y.S.K., K.-H.L., D.-Y.K., K.Y.C., K.-T.K.); School of Biological Sciences, Nanyang Technological University, Singapore 637551 (G.C., H.S.Y.); Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang, 790-784, Republic of Korea (K.-T.K.)
Running title:
Obtusilactone B targets nuclear envelope dynamics

Corresponding author information:
Kyong Tai Kim, Ph.D, Professor
Laboratory of molecular neurophysiology, Department of Life Science, POSTECH
Hyojadong, Pohang, Kyungbuk, Korea 790-784
Tel: 82-54-279-2297
E-mail: ktk@postech.ac.kr

The number of text pages: 29
The number of tables: 1
The number of figures: 6
The number of references: 32
The number of words in abstract: 197
The number of words in introduction: 683
The number of words in discussion: 647

List of nonstandard abbreviations
BAF: barrier-to-autointegration factor
VRK1: vaccinia-related kinase 1
GST: glutathione-S-transferase
EGFP: enhanced green fluorescent protein
SPR: surface plasmon resonance
Abstract

Targeting specific molecules is a promising cancer treatment because certain types of cancer cells are dependent on specific oncogenes. This strategy led to the development of therapeutics that employ monoclonal antibodies or small molecule inhibitors. However, the continued development of novel molecular targeting inhibitors is required to target the various oncogenes associated with the diverse types and stages of cancer. Obtusilactone B is a butanolide derivative purified from Machilus thunbergii. Here, we show that obtusilactone B functions as a small molecule inhibitor, that causes abnormal nuclear envelope dynamics and inhibits growth by suppressing vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF). BAF is important in maintaining lamin integrity, which is closely associated with diseases that include cancer. Specific binding of obtusilactone B to BAF suppressed VRK1-mediated BAF phosphorylation and the subsequent dissociation of the nuclear envelope from DNA that allows cells to progress through the cell cycle. Obtusilactone B potently induced tumor cell death in vitro, indicating that specific targeting of BAF to block cell cycle progression can be an effective anti-cancer strategy. Our results demonstrate that targeting a major constituent of the nuclear envelope may be a novel and promising alternative approach to cancer treatment.
Introduction

Targeted cancer therapy and personalized cancer therapeutics are aimed at a particular protein or even its polymorphic subtypes rather than common cellular factors shared by all proliferating cell types. This strategy is now anticipated to be effective against many kinds of tumors. In light of targeted cancer therapy concepts, determining the appropriate candidate oncogene to target with small molecules or monoclonal antibodies is very important. To date, most drugs in this category have been developed against oncogenic receptor tyrosine kinases or mitotic cellular kinases.

Because the rapid proliferation associated with the mutation of various growth factor receptors is an obvious cause of cancer, much effort has been spent developing drugs against these receptors. However, cell cycle-related proteins have recently drawn great attention from many researchers. Compared with extracellular growth factor receptors or secreted proteins, cell cycle-related intracellular factors play more fundamental and initiating roles, and therefore, can be more reliably targeted for drug development than traditional target proteins. For example, polo-like kinase 1 and aurora kinase B are involved in colorectal and lung cancers respectively, and have been added to the list of best target candidates for drug development (Lapenna and Giordano, 2009).

Here, we describe a kinase essential to normal mitosis, vaccinia-related kinase 1 (VRK1), which is highly expressed in fetal and cancerous tissues (Nezu et al., 1997). VRK1 plays a major role in cell cycle progression by phosphorylating histone H3 and barrier-to-autointegration factor (BAF), leading to chromatin condensation and nuclear envelope breakdown respectively (Kang et al., 2007; Nichols et al., 2006). VRK1-mediated BAF phosphorylation is one of the most important events in both mitosis and meiosis (Lancaster et al., 2007; Nichols et al., 2006). BAF is highly conserved and is important in the regulation of
nuclear architecture (Margalit et al., 2007; Skoko et al., 2009). During the resting G0 phase, a complex of genomic chromatin and BAF is tethered to the nuclear envelope by various nuclear membrane protein complexes that contain lamina-associated polypeptide 2/emerin/Man1 domains (Furukawa et al., 2003). This link between chromatin and the nuclear envelope must be disrupted to allow the cell to cycle from G0 into S phase and into the subsequent G2/M phase. Once the link is disrupted, VRK1 phosphorylates BAF (Lancaster et al., 2007; Nichols et al., 2006), and the phosphorylated BAF releases DNA from the nuclear envelope; this release is followed by DNA synthesis, transcription factor binding, and DNA condensation (Haraguchi et al., 2007; Lancaster et al., 2007; Margalit et al., 2007). Furthermore, VRK1 is also involved in the G1/S transition and the entry into mitosis (Kang et al., 2008; Lopez-Sanchez et al., 2009; Valbuena et al., 2008). Because of their prominent roles in tumorigenesis, we proposed the oncogene VRK1 and its cognate substrate BAF as novel targets of molecular medicine and thus initiated a search for small molecule inhibitors of VRK1 and BAF.

We acquired a natural herb library in which to search for small molecule inhibitors of VRK1. This system has certain merits compared to synthetic or inorganic libraries. Natural products have played a significant role in drug discovery and specifically in the development of new anti-cancer agents; more than 79.8% of the anti-cancer drugs introduced from 1981 to 2008 were natural products, semisynthetic analogues, or synthetic compounds based on natural-product pharmacophores (Cragg et al., 2009).

To find inhibitory molecules of VRK1, we performed high through-put screening of compounds derived from Machilus thunbergii Sieb. et Zucc. (Lauraceae), a deciduous tree of Korea and Japan. M. thunbergii has long been used as a traditional medicine in Korea, China and Japan to treat various diseases including edema, abdominal pain, and abdominal
distension. Next, we characterized four butanolide derivatives whose hexane subfractions prominently inhibited the phosphorylation of BAF by VRK1. Further characterization by surface plasmon resonance (SPR) detection and nuclear magnetic resonance titration of the most promising VRK1 inhibitor, obtusilactone B, demonstrated that the inhibitor specifically bound the substrate BAF. This interaction suppressed the phosphorylation of BAF by VRK1, thus arresting the cell cycle by causing defective mitotic nuclear envelope dynamics. We also showed preferential cytotoxicity of obtusilactone B toward tumor cells via cell viability assays.
Materials and Methods

NMR titration of recombinant BAF with inhibitors.

Binding modes of the small molecule BAF inhibitors were examined by studying the 2D $^1$H, $^{15}$N-Heteronuclear Single Quantum Correlation Spectroscopy (HSQC) spectrum of recombinant BAF protein before and after addition of the inhibitors. For this, the recombinant BAF protein was uniformly labeled using $^{15}$N-ammonium chloride and purified according to previously described protocol (Cai et al., 1998). HSQC spectrum of BAF was recorded using 0.3 mM protein sample on a Bruker Avance 700 spectrometer at 298 K. Ligands were then added to the sample and the chemical shifts were compared before and after the addition of the ligand. A plot of average chemical perturbations versus the amino acids was studied according to the previously described method (Chakraborty et al., 2012).

Protein Ligand Docking studies

GOLD 5.0 (Genetic Optimization for Ligand Docking, Cambridge Crystallographic Data Centre, UK) program (Verdonk et al., 2003) was used for docking studies. The crystal structure BAF protein in complex with DNA (PDB 2BZF) (Bradley et al., 2005) was prepared for docking studies by deleting the heteroatoms; assigning the charges and potentials by CHARM force field and energy minimized with conjugate gradients algorithm in Discovery Studio (DS) 3.1 (Accelrys, 2011). The ligands compound #1 & compound #3 were built with 3D-sketcher and energy minimized with smart minimizer algorithm module in DS 3.1 and thus minimized molecules were used for docking studies. An active site radius of 10.0 Å around DNA binding region of BAF was used to define the active site point and default docking parameters were employed to dock the compound #1, compound #3 into the DNA binding site of BAF.
Plant Material and Purified Compound Identification.

The stems of *Machilus thungergii* were purchased from an oriental drug store in Pohang, Gyeongbuk, Korea, in July 2009. Plant material was identified by Yong-Ki Park (Department of Herbalogy, College of Oriental Medicine, Dongguk University, Gyeongju, Korea). A voucher specimen (MT2009-01) is reserved at the Laboratory of Molecular Neurophysiology, POSTECH, Pohang, Korea. Optical rotation was measured on a JASCO P-1020 polarimeter. The infra-red (IR) spectrum was obtained with a Perkin-Elmer Spectrum GX FT-IR spectrometer. EI-MS spectra were obtained with a WATERS Micromass Platform II mass spectrometer or Agilent 7890A-5975C GC/MSD. $^1$H-NMR, $^{13}$C-NMR, DEPT, COSY, HMBC and HMQC NMR spectra were recorded on a Bruker DRX-500 FT-NMR spectrometer and a Bruker Avance 700 spectrometer. Chloroform-$d_1$ with TMS as internal standard was purchased from Sigma (St. Louis, MO, USA). Merck Silica gel 60 (63~200 μm) and LiChroperp RP-18 (40~63 μm) were used for column chromatography. Analytical TLC was performed on Merck Silica gel 60 F-254 and Silica gel 60 RP-18 F-254 TLC plates. Spots were detected by UV light (254 and 365 nm) and spraying with 10% H$_2$SO$_4$ and then heating on a hot plate.

NMR Characterization of Natural Compounds

Compounds #1~#4 were characterized by comparison of their spectroscopic data including NMR, MS and IR with literature values (Anderson et al., 1992; Hiroyuki Karikome, 1991; Kuo et al., 2008; Masatake Niwa, 1975).

**Obtusilactone B (#1):** yellowish oil. IR (KBr, cm$^{-1}$): 3575, 3000, 1790, 1685; EI/MS m/z : 335 [M+H]$^+$, 334[M]$^+$, 317[M+H-H2O]$^+$, 291[M-43]$^+$, 179, 177, 140, 135, 126, 123, 109,
97, 95, 83, 81, 79, 70, 69, 67, 57, 55, 43, 41; $^1$H-NMR (500 MHz, CDCl$_3$, δ): 6.69 (1H, td, J=8.0, 2.0 Hz, H-1’), 5.35(2H, m, H-7’, 8’), 5.12 (1H, br s, H-4), 4.89 (1H, dd, J=3.5, 2.0 Hz, H-6b), 4.68 (1H, dd, J=3.0, 1.0 Hz, H-6a), 2.78 (2H, m, H-2’), 2.03 (2H, m, H-6’), 2.03 (2H, m, H-9’), 1.50 (2H, qui, J=7.0 Hz, H-3’), 0.90 (3H, br t, J=7.0 Hz, H-16’); $^{13}$C-NMR (125 MHz, CDCl$_3$, δ): 165.3 (C-2), 157.6 (C-5), 151.2 (C-1’), 130.2 (C-8’), 129.4 (C-7’), 126.9 (C-3), 90.2 (C-6), 68.8 (C-4), 31.9 (C-14’), 29.8~29.9 (C-4’,5’,10’~13’), 28.6 (C-2’), 28.3 (C-3’), 27.2 (C-9’), 27.0 (C-6’), 22.7 (C-15’), 14.1 (C-16’).

Secosubamolide A (#2): pale yellowish liquid. IR (KBr, cm$^{-1}$): 3450, 1735, 1710; EI/MS m/z : 369 [M+H]$^+$, 351[M+H$_2$O]$^+$, 325[M-43]$^+$, 293, 265, 247, 191, 149, 125, 115, 97, 83, 69, 55; $^1$H-NMR (500 MHz, CDCl$_3$, δ): 7.09 (1H, t, J=7.5 Hz, H-3), 4.92 (1H, br s, H-1’), 3.75 (3H, s, OMe), 2.38 (2H, q, J=7.5 Hz, H-4), 2.17 (3H, s, H-3’), 1.53 (2H, qui, J=7.5 Hz, H-5), 0.90 (3H, br t, J=7.0 Hz, H-18’); $^{13}$C-NMR (125 MHz, CDCl$_3$, δ): 206.3 (C-2’), 166.5 (C-1), 149.1 (C-3), 129.7 (C-2), 73.4 (C-1’), 52.0 (OMe), 31.9 (C-16), 29.7~29.3 (C-6~15), 28.7 (C-5), 28.7 (C-4), 24.8 (C-3’), 22.7 (C-17), 14.1 (C-18).

2-Octadecylidene-3-hydroxy-4-methylenebutanolide (#3): solid. IR (KBr, cm$^{-1}$): 3584, 3350, 3020, 2935, 2860, 1780, 1680, 1665, 1465, 1270, 1205, 1145, 1060, 1015, 950, 860, 830, 815; EI/MS m/z : 365 [M+H]$^+$, 346[M]$^+$, 329[M-H$_2$O]$^+$, 313[M-45]$^+$, 140, 135, 126, 123, 109, 97, 85, 81, 79, 70, 69, 67, 57, 55, 43, 41; $^1$H-NMR (500 MHz, CDCl$_3$, δ): 7.05 (1H, td, J=8.0, 2.0 Hz, H-1’), 5.22 (1H, br d, H-4), 4.93 (1H, dd, J=3.0, 2.0 Hz, H-6b), 4.70 (1H, dd, J=3.0, 1.0 Hz, H-6a), 2.45 (2H, m, H-2’), 1.52 (2H, qui, J=7.5 Hz, H-3’), 0.88 (3H, br t, J=7.0 Hz, H-18’); $^{13}$C-NMR (125 MHz, CDCl$_3$, δ): 166.8 (C-2), 157.7 (C-5), 150.1 (C-1’), 127.4 (C-3), 91.2 (C-6), 66.4 (C-4), 31.9 (C-16’), 29.7~29.4 (C-2’, 4’~15’), 28.3 (C-3’), 22.7 (C-17’), 14.1 (C-18’).

Linderanolide (#4): crystals. IR (KBr, cm$^{-1}$): 3395, 2920, 2850, 1779, 1770, 1671, 1469,
MOL #82578

1275, 1033, 948, 863, 718; EI/MS m/z : 337 [M+H]+, 336[M]+, 319[M+H-H2O]+, 293[M-43]+, 140, 135, 126, 123, 109, 97, 95, 83, 81, 79, 70, 69, 67, 57, 55, 43, 41; 1H-NMR (500 MHz, CDCl3, δ): 6.69 (1H, td, J=8.0, 2.0 Hz, H-1’), 5.12 (1H, br d, H-4), 4.89 (1H, dd, J=3.0, 2.0 Hz, H-6b), 4.68 (1H, dd, J=3.0, 1.0 Hz, H-6a), 2.78 (2H, m, H-2’), 1.49 (2H, qui, J=7.0 Hz, H-3’), 0.89 (3H, br t, J=7.0 Hz, H-16’); 13C-NMR (125 MHz, CDCl3, δ): 165.2 (C-2), 157.6 (C-5), 151.3 (C-1’), 126.8 (C-3), 90.3 (C-6), 68.9 (C-4), 31.9 (C-14’), 29.7~29.3 (C-4’~13’), 28.7 (C-2’), 28.3 (C-3’), 22.7 (C-15’), 14.1 (C-16’).

Extraction and Isolation

The dried stems of Machilus thunbergii (20 kg) were extracted with n-hexane (40 L × 2) at room temperature. The extract was obtained by concentration under reduced pressure. The n-hexane extract (50 g among a total of 151 g) was chromatographed over silica gel (70-230 mesh, 7.5× 12 cm) and eluted with a gradient of n-hexane-EtOAc (6:1, 4:1, 2:1, and 1:1) and acetone to produce eleven fractions (MTH1~MTH11). Fraction MTH5+6 (5.35 g) was subjected to a silica gel column chromatography (4.5×15 cm), eluted with n-hexane-EtOAc (7:1) to obtain 11 fractions (MTH5+6-1~MTH5+6-11). Fraction MTH5+6-4+5 (1.75 g) was purified by an octadecyl silica gel (ODS) column chromatography (4×5 cm) and eluted with MeOH -H2O (13:1) to ultimately produce compound 3 (80.0 mg). Fraction MTH7+8 (1.7 g) was subjected to a silica gel column chromatography (4.5×15 cm), eluted with CHCl3-acetone (100:1) to obtain 11 fractions (MTH7+8-1~MTH7+8-11). Fraction MTH7+8-4 (1.3 g) was applied to an ODS column chromatography (4×6 cm) and eluted with MeOH -H2O (9:1, 10:1 and 12:1) to produce compound 1 (50 mg), compound 2 (31 mg) and compound 4 (35 mg).
Cell culture, Transfection and Flow Cytometry

A549 cell was cultured in RPMI-1640 medium (Welgene, Korea) containing 10% of fetal bovine serum (Hyclone, USA) and 1% penicillin/streptomycin (Welgene, Korea) in a humidified 5% CO₂ incubator at 37°C. B16F-10 cell was fed in DMEM medium. Transient transfection was performed by a microporator MP-100 (Invitrogen, USA) according to manufacturer’s instruction (1300V, 20ms, #2). For flow cytometric analysis, cells were fixed with 70% ethanol containing 0.4% Tween-20. Cellular DNA was stained with 50 μg/ml of propidium iodide (Fluka, USA) and 100 μg/ml of RNase A (Sigma, USA) in PBS. Sample containing 5,000 cells were analyzed on a FACSCalibur system (BD, USA).

Plasmids, Antibody, Recombinant Protein Purification and in vitro Kinase Assay

To generate barrier-to-autointegration factor (BAF) expression construct, full-length BAF was amplified by PCR from HeLa cells. For mammalian expression, DNA fragment coding for BAF was cloned into pEGFP-C1 (Clontech Laboratories, USA). GST-tagged VRK1 and histidine-tagged BAF were prepared as previously described (Harris and Engelman, 2000; Kang et al., 2008). For red fluorescent protein-tagged VRK1, DNA fragment coding for VRK1 was cloned into pDsRed-Monomer-N1 (Clontech Laboratories, USA). In vitro kinase assay between recombinant VRK1 and BAF was performed as previously described (Kim et al., 2011). Antibody against Lamin A/C (N-18) was purchased from Santa Cruz.

Surface Plasmon Resonance (SPR)

The interaction between the BAF and obtusilactone B was analyzed by SPR, using the Reichert SR7500DC system (Reichert Technologies, USA) and data collection software (SPR Autolink v1.1.8G). BAF protein, the ligand, was covalently bound to carboxymethyl dextran...
sensor chip (CMDH gold slide) with 1-ethyl-3(3-dimethylaminopropyl) carbodiimide-HCl (EDC) and N-hydroxysuccinimide (NHS). The ligand was bound at densities about 2400 RU, where RU, resonance units, 1RU = 1pg/mm² on the sensor surface. Obtusilactone B and 2-octadecylidene-3-hydroxy-4-methylenbutanolide, the analytes, were injected over the sensor surface at the indicated concentrations diluted in 10mM phosphate-buffered saline containing 1% of DMSO. RUs were recorded in real time before and during small molecule injection (1 minute) and during washout (2 minutes). Analysis of steady-state affinity was performed using Scrubber2 software selecting reference-subtracted curves. Recorded responses that included disturbances produced by air bubbles, aggregation, or precipitation of analytes were discarded. In the global approach all the samples, including both association and dissociation steps, are fit at the same time using a sum of squared residuals over every data point.

*Dye Conjugation*

Obtusilactone B was covalently conjugated with a red fluorescent dye, FPR552 (Bioacts, Korea – λ abs : 551nm, λ em : 570nm). Ethanol-solubilized obtusilactone B and FPR552 were reacted in dimethylformamide and then 0.1M phosphate buffer (pH 12.0) was added. After 4 hours of incubation at room temperature, the FPR552-obtusilactone B conjugates were lyophilized and purified under Agilent 1100 series HPLC system using Jupiter 10u C18 300A 250X10mm column.

*Cell Viability Assay*

Cell viability was assessed by measuring the activity of metabolizing 3-(4,5-dimethylidiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Choi et al., 2008). 1.0 x 10⁴ cells were seeded onto 96-well plate and cultured up to confluency of 90%. After treating indicated
concentration of inhibitors for 24 hours, cells were treated with MTT solution and cell viability was assessed.
Results

Small molecule inhibitors of BAF phosphorylation

To find small molecule inhibitors of VRK1, we analyzed hundreds of natural herb extracts prepared by extraction of Korean traditional herbs in 80% methanol (Supplemental Figure 1). Among them, the crude extract of *M. thunbergii* substantially inhibited the autophosphorylation of VRK1. We next conducted *in vitro* kinase assays with *M. thunbergii* to find inhibitory molecules against VRK1 action by performing solvent-based extraction and purifying active sub-fractions (Fig. 1A). Certain fractions derived from hexane and butyl alcohol extraction completely inhibited the catalytic activity of VRK1 towards BAF. We further fractionated the hexane extract to purify the bioactive inhibitor molecule (Fig. 1B). We successfully isolated and characterized four bioactive butanolides: obtusilactone B (compound #1), secosubamolide A (compound #2), 2-octadecylidene-3-hydroxy-4-methylenebutanolide (compound #3), and linderanolide (compound #4). This study describes the first isolation of compounds #1, #2, and #4 from *M. thunbergii* (Fig. 1C).

Obtusilactone B suppresses VRK1-mediated phosphorylation of BAF

VRK1 is a cell cycle-regulating protein kinase and acts on several related substrates that include p53, histone H3, BAF, and CREB (Kang et al., 2007; Kang et al., 2008; Nichols et al., 2006; Valbuena et al., 2008). Because BAF is one of the most important substrates of VRK during mitosis, during which BAF phosphorylation is required for DNA condensation and mitotic progression (Suzuki et al., 2010; Vlcek et al., 2001), we primarily analyzed whether our novel butanolide derivatives suppressed the enzymatic reaction of VRK1 toward BAF (Fig. 2A). Although two derivatives inhibited BAF phosphorylation, inhibition by obtusilactone B (compound #1) was the most pronounced. We next serially diluted
obtusilactone B to estimate its median inhibitory concentration (Fig. 2B) and found that obtusilactone B strongly inhibited BAF phosphorylation by VRK1 in vitro with a median inhibitory concentration of 0.8 μM. Interestingly, obtusilactone B inhibited VRK1 autophosphorylation very little, indicating that rather than occupying the ATP-binding domain or another conserved domain as many kinase inhibitors do, obtusilactone B may inhibit the interaction between VRK1 and BAF. We next tested other VRK1 substrates to confirm the inhibitory activity observed. To our surprise, obtusilactone B did not inhibit the catalytic activity of VRK1 toward histone H3 or casein peptide (Fig. 2D and 2E) even though it inhibited BAF phosphorylation (Fig. 2C); this observation suggests that obtusilactone B specifically inhibits the interaction between VRK1 and BAF.

**Obtusilactone B specifically interacts with BAF**

To understand the molecular basis of the interaction between obtusilactone B and BAF suggested by the in vitro kinase assays, we studied the interaction between 15N-labeled recombinant BAF and obtusilactone B by nuclear magnetic resonance spectroscopy (Fig. 3A). Chemical shift perturbations observed in the heteronuclear single quantum coherence spectrum of BAF upon addition of the ligands obtusilactone B and 2-octadecylidene-3-hydroxy-4-methylenebutanolide were analyzed and mapped on the surface of BAF (Fig. 3B). Obtusilactone B binds BAF strongly, as indicated by dramatic chemical shift perturbations observed upon the addition of the ligand to the protein. In contrast, the inactive ligand 2-octadecylidene-3-hydroxy-4-methylenebutanolide binds the protein weakly, as evidenced by smaller changes upon the addition even of high molar ratios of the inactive ligand (e.g., 10:1 2-octadecylidene-3-hydroxy-4-methylenebutanolide : BAF, data not shown). The residues whose backbone amide resonance was dramatically affected by the obtusilactone B
interaction included S22, A24, K32, G31, and E35 (Fig. 3A). These residues are located near the protein’s helix-loop-helix region, which plays a major role in its interaction with double stranded DNA molecules (Bradley et al., 2005). Other residues, such as D9, Q73, and D76, also exhibited chemical shift perturbations in our study. An overlay of the heteronuclear single quantum coherence spectrum of the free BAF protein and the bound protein (1:1 molar ratio obtusilactone B : BAF) is presented in Supplemental Figure 2.

**In silico modeling and analysis of the binding mode of obtusilactone B**

Obtusilactone B clearly bound near the DNA binding site of BAF (Bradley et al., 2005). The hexadec-7-enylidene bond of the obtusilactone B molecule seems to interact favorably with the glycine-rich region of BAF, forming tight van der Waal contacts with residues G21, G25, G29, and G31. The 4-hydroxy-5-methylene-dihydro-furan-2-one moiety of obtusilactone B is stabilized by hydrogen bonding with residue E28 and hydrophobic interactions with residues V20, G25, I26, V29, L30, G31, and K32 in the hydrophobic groove (Fig. 3D). In contrast, the same moiety of 2-octadecylidene-3-hydroxy-4-methylenebutanolide fails to form these interactions and drifts away from the active pocket. The failure to interact with E28, the lack of unsaturated bonds, and a carbon chain lengthier by two atoms are probable reasons for the inactivity of 2-octadecylidene-3-hydroxy-4-methylenebutanolide (Fig. 3D). Taken together, our results suggest that obtusilactone B suppresses the VRK1-mediated phosphorylation of BAF specifically by binding near the DNA binding site of BAF. It is unclear whether this region is important in the interaction between VRK1 and BAF. However, the specific interaction between obtusilactone B and the N-terminal region of BAF, proximal to residues phosphorylated by VRK1 (Nichols et al., 2006), indicates the possible identification of obtusilactone B as a novel small molecule inhibitor that targets a major nuclear envelope
SPR evidence for the interaction of obtusilactone B with BAF

The interaction between BAF and obtusilactone B was further evidenced by SPR analysis and cytochemistry with fluorescent dye-conjugated obtusilactone B. SPR employs various biosensor systems to detect molecular interactions (Karlsson et al., 1991). We immobilized the BAF protein to a gold sensor chip slide and applied obtusilactone B to the slide. Sensor chip-immobilized BAF protein was more sensitive to obtusilactone B than to 2-octadecylidene-3-hydroxy-4-methylenebutanolide (Fig. 4A). Calculated binding constants are presented in Table 1. As previous results suggest, obtusilactone B, the inhibitor of VRK1-mediated BAF phosphorylation, exhibited a higher binding affinity for BAF than did 2-octadecylidene-3-hydroxy-4-methylenebutanolide. Unreferenced raw data and responses of immobilized VRK1 protein are also presented in Supplemental Figure 3. These results suggest that obtusilactone B specifically binds to BAF, but does not bind VRK1.

Expression of enhanced green fluorescent protein-labeled BAF induced the localization of FPR552-conjugated obtusilactone B to the nucleus, to which native BAF protein localizes (Fig. 4B and 4C). In contrast, neither the unconjugated dye FPR552 nor enhanced green fluorescent protein co-localized with each other. Taken together, our data suggest that obtusilactone B, a small molecule inhibitor of BAF phosphorylation, specifically interacts with BAF near the protein’s DNA binding region, thereby inhibiting BAF phosphorylation by VRK1.

Physiological perturbations induced by obtusilactone B treatment

As mentioned above, BAF plays an important role in nuclear envelope structure (Vleek et
The interactions and dynamics of nuclear membrane proteins must be tightly coordinated during many cellular processes including cell cycle progression (Furukawa et al., 2003; Gorjanacz et al., 2007; Lancaster et al., 2007). Specifically, the interaction between chromatin and the nuclear envelope must be disrupted at the G1/S transition that occurs at the beginning of the cell cycle. At this stage, BAF is phosphorylated by VRK1, and next, chromatin is released from the nuclear envelope (Lancaster et al., 2007; Nichols et al., 2006).

We visualized the mitotic nuclear envelope fragment by staining nuclear lamin A/C of A549 cells (Fig. 5A) and found that nuclear lamin A/C was dispersed into the cytosol at late anaphase. However, this release was completely abolished by treatment with obtusilactone B: compared with vehicle-treated cells, A549 cells grown in medium containing obtusilactone B could not release the nuclear envelope fragment containing lamin A/C from chromatids. This inability to release the fragment might be attributed to the inhibitory action of obtusilactone B on the phosphorylation of BAF by VRK1. To further analyze this cellular effect, we expressed VRK1 and BAF in concert with obtusilactone B treatment (Fig. 5B). As previously demonstrated (Nichols et al., 2006), co-expression of BAF and VRK1 induced their translocation into the cytosol, and this translocation was accompanied by DNA condensation. However, in obtusilactone B-treated cells, BAF could not translocate into the cytosol but was trapped by the contorted nucleus despite the presence of VRK1. These results indicate that obtusilactone B blocked BAF phosphorylation by VRK1, resulting in dysfunctional cellular processes. Because the phosphorylation of BAF is involved in cell cycle initiation, we quantitatively assessed the DNA content of obtusilactone B-treated cells by flow cytometry (Fig. 5C and 5D). The A549 cell population treated with obtusilactone B included a significantly increased number of cells in the G1 phase, which possibly resulted from the defective DNA release from the nuclear envelope during the G1/S transition and the
subsequent delay in cell cycle progression. This defect was successfully rescued by the introduction of GFP-tagged BAF protein suggesting that obtusilactone B-induced cell cycle arrest was induced by the silencing of endogenous BAF.

Anti-cancer activity of obtusilactone B

Because the suppression of BAF phosphorylation by VRK1 in obtusilactone B-treated cells appeared to trigger defective cell cycle progression, we next analyzed the anti-tumor activity of obtusilactone B. First, we performed a cell viability assay to provide evidence for the proposed molecular mechanism of interference with cell growth or viability. The obtusilactone B was moderately cytotoxic to A549 (Fig. 6A) and HeLa (Fig. 6B) cells. However, 2-octadecylidene-3-hydroxy-4-methylenebutanolide was significantly less cytotoxic than obtusilactone B. We assume that the difference in cytotoxicity is derived from the ability of obtusilactone B to specifically target endogenous proteins such as BAF.

We also analyzed the specificity of obtusilactone B against tumor cells versus normal cells. We prepared mouse embryonic fibroblast derived from the C57BL/6 strain as a normal cell control. B16F10, a metastatic melanoma fibroblast line derived from the C57BL/6 strain was prepared as the cancer cell control. As shown in Fig. 6C, obtusilactone B effectively killed metastatic melanoma cells. However, mouse embryonic fibroblast cells were quite resistant to obtusilactone B compared to melanoma cells. This result shows that obtusilactone B might target highly proliferative cancer cells with specificity. Obtusilactone B also effectively killed teratocarcinoma cells at very low concentrations approaching 1 μM (Fig. 6D).

The effect of obtusilactone B on aneuploidy was assessed by analyzing the molecule’s effect on a cell population containing DNA content more than 4N (Fig. 6E and 6F). Treatment with 10 μM obtusilactone B for 72 hours effectively induced cell death in the aneuploid cell
population, but not in the euploid cell population. Together, these results suggest that the novel small molecule inhibitor, obtusilactone B, preferentially targets oncogenic cells by blocking the cellular functions of BAF protein.

**Discussion**

Genomic DNA is attached to the nuclear envelope during interphase via the interaction of the core nuclear envelope constituents lamin and BAF (Margalit et al., 2007). The interaction between DNA and the nuclear envelope is very important for nuclear integrity and must thus be tightly regulated throughout the cell cycle. Progression of the cell cycle requires a disruption of the link between DNA and the nuclear envelope, which is achieved by VRK1-mediated BAF phosphorylation (Nichols et al., 2006). This process is very important for various cell functions; thus Baf is well conserved from *Drosophila melanogaster* to *Homo sapiens*.

Here, we report a small molecule inhibitor, obtusilactone B, that targets BAF and inhibits VRK1-mediated phosphorylation. Obtusilactone B interacts with BAF specifically and suppresses subsequent VRK1-mediated BAF phosphorylation. Specific binding of obtusilactone B to cellular BAF causes an aberrant interaction between DNA and the nuclear envelope during the mitotic phase. We also demonstrated that obtusilactone B targets tumor cells and selectively kills aneuploid cells *in vitro*.

However, more detailed molecular mechanistic studies should be performed to conclude that obtusilactone B has genuine specificity for cancer cells. Such studies could include a systemic approach to phosphor-profiling of BAF protein in various cancer tissues. Additional evidence including animal experiment should also be obtained.
The nuclear envelope has not been a primary target in anti-cancer drug development. However, like other important cellular factors, nuclear envelope constituents play major roles in the regulation of proliferative gene expression and genome integrity (Chow et al., 2012). Among the nuclear envelope constituents, lamin is a key physiological regulator, and the association of lamin dysfunction with various diseases has been frequently reported recently (Burke and Stewart, 2006; Chow et al., 2012; Gonzalez-Suarez et al., 2009). These reports suggest that effective targeting of nuclear envelope constituents awaits the advent of a novel cancer drug that targets proteins such as BAF. We posit that obtusilactone B specifically targets the core nuclear envelope constituent, BAF and blocks abnormal cell division of tumor cells by inhibiting VRK1-mediated phosphorylation of BAF. A strategy targeting the action of VRK1 toward BAF might have potential therapeutic use in BAF-related abnormalities, including various cancers.
Authorship Contributions

Participated in research design: W.Kim, KY. Choi, HS.Yoon, KT.Kim

Conducted experiments: W.Kim, HS. Kwon, HN.Lyu, KH.Lee, DY.Kim, YS. Kim

Performed data analysis: W.Kim, G. Chakraborty, H.S.Yoon, KT.Kim

Wrote or contributed to the writing of the manuscript: W.Kim, HN.Lyu, HS.Yoon, KT.Kim
References


Footnotes

This work was supported by grants from the National Research Foundation of Korea (NRF) [Nos. 20110027957, 20110031234, 20120005830, 20110031517], the Brain Korea 21 program, the World Class University program [R31-10105] funded by the Korean Ministry of Education, Science, and Technology (MEST), and Singapore Ministry of Education AcRF Tier 2 Grant (ARC 25/12). We thank Amaravadhi Harikishore for his help on protein ligand docking. W.K., H.-N.L., and H.-S.K. contributed equally to this work.
Figure legends

Fig. 1 Small molecule inhibitors of BAF phosphorylation

A, Crude extracts from *M. thunbergii* solubilized into indicated solvents were added to *in vitro* kinase reaction of BAF by recombinant GST-VRK1. B, Five kinds of butanolide derivatives were purified from hexane sub-fraction. Each purified compound was added into *in vitro* kinase reaction to final concentration of 100 μM. Autoradiography was acquired and proteins were stained with SYPRO Ruby. C, Chemical structures of compound 1~4. #1; Obtusilactone B, #2; Secosubamolide A, #3; 2-Octadecylidene-3-hydroxy-4-methylenebutanolide, #4; Linderanolide

Fig. 2 Obtusilactone B suppresses VRK1-mediated phosphorylation of BAF

A, Purified butanolide derivatives from *M. thunbergii* were added into *in vitro* kinase reaction between recombinant VRK1 and BAF to final concentration of 100 μM. Autoradiography was acquired and proteins were stained with SYPRO Ruby. B, Inhibitory activity of four butanolide derivatives was assayed. The autoradiography of each compound was quantitated by densitometry. C, *In vitro* kinase assay of BAF by recombinant GST-VRK1 was performed. The kinase reaction was performed in the varying amounts of obtusilactone B ranging to 100 μM. D-E, *In vitro* kinase assay of histone H3 and casein by recombinant GST-VRK1 were performed. Autoradiography was acquired and proteins were stained with SYPRO Ruby or Coomassie Brilliant Blue.

Fig. 3 Obtusilactone B specifically interacts with BAF

A, A plot of average chemical shift perturbations versus amino acid residues of BAF protein on addition of obtusilactone B in a 1:1 molar ratio. B, Mapping of the chemical shift
perturbations on BAF (PDB ID 2BZF) protein. The interacting residues (shown in yellow), are close to DNA binding region of BAF. C-D, Molecular docking analyses of the butanolide derivatives with BAF protein. Interaction of obtusilactone B with modeled BAF protein was shown in yellow sticks and 2-octadecylidene-3-hydroxy-4-methylenebutanolide otherwise in blue. The heterocyclic moiety in obtusilactone B is stabilized in the hydrophobic groove by hydrogen bonding with the E28 residue (shown in dashed lines) and hydrophobic contacts with V20, G25, I26, V29, L30, G31 and K32 (shown in dotted lines) residues while 2-octadecylidene-3-hydroxy-4-methylenebutanolide the same moiety lacks these interactions.

**Fig. 4 SPR evidence for the interaction of obtusilactone B with BAF**

A, Sensorgram overlays for the binding of obtusilactone B (red) and 2-octadecylidene-3-hydroxy-4-methylenebutanolide (blue) to BAF protein immobilized on a CMDH gold sensor chip. Shown are the binding responses (arbitrary unit) of each analyte injected at 2, 4, and 8μM over the surface. B, Obtusilactone B conjugated with FPR552 was separated by thin layer chromatography of silica gel developed with solvent system acetonitrile/water (1:2). C, A549 cells were transfected with EGFP-tagged BAF for 12 hours. After fixation, FPR552-conjugated obtusilactone B was treated for 30 minutes.

**Fig. 5 Physiological perturbations induced by obtusilactone B treatment**

A, A549 cells were treated with 10 μM of obtusilactone B for 72 hours. Anti-lamin A/C antibody was applied and visualized by Alexa-488 dye. DNA was also visualized by Hoechst 33342. B, HEK293A cells were transfected with red fluorescent protein-VRK1 and EGFP-BAF. After 72 hours treatment of 10 μM of obtusilactone B, fluorescent images were captured. C-D, A549 cells were treated with 25 μM of obtusilactone B for 24 hours after transfection with EGFP or EGFP-BAF. Nuclear DNAs were stained with propidium iodide,
and flow cytometric analyses were performed.

**Fig. 6 Anti-cancer activity of obtusilactone B**

A, A549 cells were treated with indicated amount of obtusilactone B and 2-octadecylidene-3-hydroxy-4-methylenebutanolide. After 24 hours, cell viability was assessed by measuring its activity to metabolize MTT. B, HeLa cells were treated with indicated amount of obtusilactone B and 2-octadecylidene-3-hydroxy-4-methylenebutanolide. After 24 hours, cell viability was assessed by measuring its activity to metabolize MTT. C, Mouse embryonic fibroblast derived from C57BL/6 mouse and B16F10 cells were treated with indicated amount of obtusilactone B. After 24 hours, cell viability was assessed by measuring its activity to metabolize MTT. D, F9 mice teratocarcinoma cells were treated with indicated amount of obtusilactone B. Time-laps images of live cells were acquired and confluency was assessed from Incucyte software. Arrow indicates the addition of obtusilatone B. E, A549 cells were treated with 10 μM of obtusilactone B for 72 hours. DNA was stained by propidium iodide, and flow cytometric analysis was performed. Aneuploid cell population which contains DNA content more than 4N is marked.
Table 1. Binding constants between BAF and Pbtusilactone B / 2-Octadecylidene-3-hydroxy-4-methylenebutanolide

<table>
<thead>
<tr>
<th></th>
<th>Ka(M⁻¹S⁻¹)</th>
<th>Kd(S⁻¹)</th>
<th>KD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obsutilactone B</td>
<td>1.14 x 10⁴ ± 0.06</td>
<td>0.0158 ± 0.0004</td>
<td>1.39 ± 0.08 μM</td>
</tr>
<tr>
<td>2-Octadecylidene-3-hydroxy-4-methylenebutanolide</td>
<td>3.0 x 10³ ± 0.3</td>
<td>0.0366 ± 0.0007</td>
<td>12 ± 1 μM</td>
</tr>
</tbody>
</table>
Figure 1

A

<table>
<thead>
<tr>
<th>Substance</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
</tr>
<tr>
<td>Hexane</td>
</tr>
<tr>
<td>EioAc</td>
</tr>
<tr>
<td>BuOH</td>
</tr>
</tbody>
</table>


B

<table>
<thead>
<tr>
<th>Substance</th>
</tr>
</thead>
<tbody>
<tr>
<td>EioH</td>
</tr>
<tr>
<td>#1</td>
</tr>
<tr>
<td>#5</td>
</tr>
<tr>
<td>#2</td>
</tr>
<tr>
<td>#3</td>
</tr>
<tr>
<td>#4</td>
</tr>
</tbody>
</table>


C

Chemical structures

#1

#2

#3

#4
Figure 4

A

B

C

Response (RU)

Time (s)

FPR552

FPR552 + Obtusilactone B

EGFP-mock FPR552

EGFP-mock FPR552-OB

EGFP-hBAF FPR552

EGFP-hBAF FPR552-OB
Figure 5

A) Lamin A/C, Hoechst 33342, and Merge images under Vehicle and Obtusilactone B conditions.

B) RFP-VRK1, EGFP-BAF, Hoechst 33342, and Merge images under Vehicle and Obtusilactone B conditions.

C) Flow cytometry analysis of cells under Vehicle and OB 25μM conditions, showing 2n and 4n counts.

D) Flow cytometry analysis of cells under Vehicle and OB 25μM conditions, showing 2n and 4n counts.
Figure 6

(A) Graph showing cell viability (%) against concentration for Obtusilactone B and 2-Octadecylidene-3-hydroxy-4-methylenebutanolide. 

(B) Graph showing cell viability (%) against concentration for Obtusilactone B.

(C) Graph showing cell viability (%) against concentration for MEF (c57BL/6) and B16F10.

(D) Time course of confluency (%) over days 1 to 4 for different concentrations of vehicle and drug.

(E) Flow cytometry results showing aneuploid and euploid populations.

(F) Additional flow cytometry results showing euploid populations.